Adverse effects of dopamine potentiation by long-term treatment with selegiline

Movement Disorders

Volumn 19, Issue 1, 2004, Pages 107-109

  Hollán, Susan ^a   Vécsei, Lśzló ^b   Magyar, Kálmán ^c  

^a Natl Institute of Blood Transfusion   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Monoamine oxidase B; Selegiline; TPI defect; Triosephosphate isomerase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BACLOFEN; BENSERAZIDE PLUS LEVODOPA; BOTULINUM TOXIN; BROMOCRIPTINE; DOPAMINE; NITRAZEPAM; SELEGILINE; TRIOSEPHOSPHATE ISOMERASE;

ADULT; ANOREXIA NERVOSA; ARTICLE; CASE REPORT; DNA DETERMINATION; ENZYME DEFICIENCY; EXTRAPYRAMIDAL SYMPTOM; GENE MUTATION; HUMAN; INSOMNIA; INVOLUNTARY MOVEMENT; LONG TERM CARE; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; TORSION DYSTONIA; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; ANEMIA, HEMOLYTIC, CONGENITAL; ANTIPARKINSON AGENTS; BACLOFEN; BASAL GANGLIA; BASAL GANGLIA DISEASES; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; DYSTONIA MUSCULORUM DEFORMANS; FEMALE; GENOTYPE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HETEROZYGOTE DETECTION; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE TISSUE PROTEINS; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTEINS; PSYCHOSES, SUBSTANCE-INDUCED; REFERENCE VALUES; SELEGILINE; TRINUCLEOTIDE REPEATS;

EID: 17944402073     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10641     Document Type: Article

References (20)

1. Hollán S, Fujii H, Hirono A, et al. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers, one with and one without neurological symptoms. Hum Genet 1993; 92:486-490.
2. Chang ML, Artymiuk PL Wu X, Hollán S, Lammi A, Maquat LE. Human triosephosphate isomerase deficiency resulting from mutation of Phe-240. Am J Hum Genet 1993;52:1260-1269.
3. Valentin C, Cohen-Solal M, Maquat L, Horányi M, Inselt-Kovács M, Hollán S. Identical germ-line mutations in the triosephosphate isomerase alleles of two brothers are associated with distinct clinical phenotypes. C R Acad Sci III 2000;323:245-250.
4. Hollán S, Magócsi M, Fodor E, Horányi M, Harsányi V, Farkas T. Search for the pathogenesis of the differing phenotype in two compound heterozygote Hungarian brothers with the same genotypic triosephosphate isomerase deficiency. Proc Natl Acad Sci USA 1997;94:10362-10366.
5. Orosz F, Oláh J, Alvarez M. et al. Distinct behaviour of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency. Blood 2001;98:3106-3112.
6. Wurtman RJ, Axelrod J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 1963;12: 1417-1419.
7. Davies KE. Human genetic diseases: a practical approach. Oxford: IRL Press; 1986.
8. Watanabe M, Abe K, Aoki M. A reproducible assay of polymerase chain reaction to detect trinucleotide repeat expansion of Huntington's disease and senile chorea. Neurol Res 1996;18:16-18.
9. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
10. Schneider AS. Triosephosphate isomerase deficiency: historical perspectives and molecular aspects. Balliéres Best Pract Res Clin Haematol 2000;13:119-140.
11. Poll-The BT, Aicardi J, Girot R, Rosa R. Neurological findings in triosephosphate isomerase deficiency. Ann Neurol 1985;17:440-443.
12. Jakel RJ, Maragos WF. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 2000;23:239-245.
13. Olanow CW. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J Neural Transm 1996;48:75-84.
14. Magyar K. Pharmacology of monoamine oxidase type-B inhibitors and clinical use in neurodegenerative disorders. In: Szelényi I, editor. Inhibitors of monoamine oxidase-B. Basel: Birkhaus Verlag; 1993. p 125-143.
15. Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. In: Iversen LL, editor. Synaptic pharmaceutical corporation. Oxford: University of Oxford; 2001. p 8966-8971.
16. Karg E, Németh I, Horányi M, Pintér S, Vé csei L, Hollán S. Diminished blood levels of reduced glutathione and α-tocopherol in triosephosphate isomerase deficient brothers. Blood Cells Mol Dis 2000;26:91-100.
17. Collins GG, Sandler M, Williams AD, Youdim MB. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 1970;225:817-820.
18. Brunner HG, Nelen M, Breakfield XO, Ropers HH. Abnormal behaviour associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993;262:578-580.
19. Ekblom J, Garpenstrand H, Damberg M, Chen K, Shih JC, Oreland L. Transcription factor binding to the core promoter of the human monoamine oxidase B gene in the cerebral cortex and in blood cells. Neurosci Lett 1998;258:101-104.
20. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.